Prevention of Oral Mucositis in Patients undergoing Chemotherapy

Detalhes bibliográficos
Autor(a) principal: Valduga, Francielli
Data de Publicação: 2018
Outros Autores: Oltramari, Elenusa, Lemes, Letícia Tainá de Oliveira, Mattos, Carlos Eduardo de, Stefenon, Letícia, Mozzini, Carolina Barreto
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/77
Resumo: Introduction: The chemotherapy is one of the cancer possible treatments and use chemotherapeutic drugs as 5-fluorouracil (5-FU), major cause of oral mucositis. This complication is the most common cause of pain.  There is still no specific protocol for the prevention of this complication, but there are substances used empirically and palliative. Objective: Assessing the degree of mucositis during the 10 days after each chemotherapy cycle using the self-perception of each patient and the pain level reported with the use of the two substances studied: mallow tea and 0,12% chlorhexidine. Method: The selected patients were randomly randomized to perform mouthwash with 10 ml of the test substance, 3 times a day, during the infusion time of chemotherapy. In each accompanied cycle one of the studied substances were used. During the 10 days after chemotherapy, patients answered a questionnaire with closed questions about their pain and self-perception of their oral mucosa. Results: in cycles where mallow tea was used, selfperception of patients seems to be better with your oral mucositis is grade 1 and 2. However, in cycles where 0,12% chlorhexidine was used, patients experienced less pain. Conclusion: In both cycles that was used at 0.12% chlorhexidine was used as those where the mauve tea, most of the patients reported oral mucositis present. However, when used mauve tea was obtained mucositis in minor degrees. The 0.12% chlorhexidine it appeared to have less pain symptoms, although the difference was small when compared to the two substances. 
id INCA-1_76b46d27c5a6b4a6aa2d8efcf60738db
oai_identifier_str oai:rbc.inca.gov.br:article/77
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Prevention of Oral Mucositis in Patients undergoing ChemotherapyPrevención de la Mucositis Oral en Pacientes sometidos a la QuimioterapiaPrevenção da Mucosite Oral em Pacientes submetidos à QuimioterapiaMucositePrevenção & ControleClorexidinaMalvaMucositisPrevention & controlChlorhexidineMalvaMucositisPrevención & controlClorhexidinaMalvaIntroduction: The chemotherapy is one of the cancer possible treatments and use chemotherapeutic drugs as 5-fluorouracil (5-FU), major cause of oral mucositis. This complication is the most common cause of pain.  There is still no specific protocol for the prevention of this complication, but there are substances used empirically and palliative. Objective: Assessing the degree of mucositis during the 10 days after each chemotherapy cycle using the self-perception of each patient and the pain level reported with the use of the two substances studied: mallow tea and 0,12% chlorhexidine. Method: The selected patients were randomly randomized to perform mouthwash with 10 ml of the test substance, 3 times a day, during the infusion time of chemotherapy. In each accompanied cycle one of the studied substances were used. During the 10 days after chemotherapy, patients answered a questionnaire with closed questions about their pain and self-perception of their oral mucosa. Results: in cycles where mallow tea was used, selfperception of patients seems to be better with your oral mucositis is grade 1 and 2. However, in cycles where 0,12% chlorhexidine was used, patients experienced less pain. Conclusion: In both cycles that was used at 0.12% chlorhexidine was used as those where the mauve tea, most of the patients reported oral mucositis present. However, when used mauve tea was obtained mucositis in minor degrees. The 0.12% chlorhexidine it appeared to have less pain symptoms, although the difference was small when compared to the two substances. Introducción: La quimioterapia es una forma de tratamiento de cáncer y se utilizan drogas como el 5-fluorouracilo (5-FU), mayor causante de la mucositis oral. Aún no hay un protocolo específico para la prevención de esta complicación. Objetivo: Evaluar el grado de mucositis oral durante los 10 días después de cada ciclo de quimioterapia según la auto-percepción de cada paciente y el nivel de dolor relatado con el uso de las dos sustancias estudio: té de malva y clorexidina 0,12%. Método: Los pacientes fueron aleatorizados por sorteo para la realización de enjuague con 10ml de la sustancia determinada, 3 veces al día, durante el período de infusión de la quimioterapia. En cada ciclo se utilizó una de las sustancias. Durante los 10 días después de la quimioterapia los pacientes respondieron a un cuestionario con preguntas cerradas sobre su dolor y la autopercepción de su mucosa oral. Resultados: En los ciclos utilizando el té de malva la auto-percepción del paciente pareció ser mejor, con su mucositis oral siendo de  grado 1 y 2. En los ciclos utilizando clorexidina 0,12% los pacientes presentaron menos dolor. Conclusión: Tanto en los ciclos en que se utilizó la clorexidina 0,12% como en aquellos donde se utilizó el té  de malva, la mayoría de los pacientes refirió presentar mucositis oral. Sin embargo, cuando se utilizó el té de malva la frecuencia de mucositis fue en menores grados. La clorexidina 0,12% pareció presentar menos sintomatología dolorosa, a pesar de la diferencia comparando las dos sustancias haber sido pequeña. Introdução: A quimioterapia é uma das formas de tratar o câncer, na qual utilizam-se drogas como o 5-fluorouracil (5-FU), maior causador da mucosite oral. Essa complicação é a causa mais comum de dor. Objetivo: Avaliar o grau de mucosite oral durante os dez dias após cada ciclo de quimioterapia, segundo a autopercepção de cada paciente e o nível de dor relatada com o uso das duas substâncias estudo: chá de malva e clorexidina 0,12%. Método: Os pacientes foram randomizados por sorteio para a realização de bochechos com 10 ml da substância determinada, três vezes ao dia, durante o período de infusão da quimioterapia. Em cada ciclo, utilizou-se uma das substâncias. Durante os dez dias após a quimioterapia, os pacientes responderam a um questionário com perguntas fechadas sobre a sua dor e a autopercepção da sua mucosa oral. Resultados: Nos ciclos utilizando o chá de malva, a autopercepção do paciente pareceu ser melhor, com sua mucosite oral sendo de graus 1 e 2. Contudo, nos ciclos utilizando clorexidina 0,12%, os pacientes apresentaram menos dor. Conclusão: Tanto nos ciclos em que foi utilizado a clorexidina 0,12% quanto naqueles onde foi utilizado o chá de malva, a maioria dos pacientes referiu apresentar mucosite oral. Porém, quando utilizado o chá de malva, a frequência de mucosite foi em menores graus. A clorexidina 0,12% pareceu apresentar menos sintomatologia dolorosa, apesar da diferença, comparando as duas substâncias, ter sido pequena.INCA2018-06-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/7710.32635/2176-9745.RBC.2018v64n2.77Revista Brasileira de Cancerologia; Vol. 64 No. 2 (2018): Apr./May/June; 189-194Revista Brasileira de Cancerologia; Vol. 64 Núm. 2 (2018): abr./mayo/jun.; 189-194Revista Brasileira de Cancerologia; v. 64 n. 2 (2018): abr./maio/jun.; 189-1942176-974510.32635/2176-9745.RBC.2018v64n2reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/77/37https://rbc.inca.gov.br/index.php/revista/article/view/77/153Valduga, FrancielliOltramari, ElenusaLemes, Letícia Tainá de OliveiraMattos, Carlos Eduardo deStefenon, LetíciaMozzini, Carolina Barretoinfo:eu-repo/semantics/openAccess2021-11-29T20:06:43Zoai:rbc.inca.gov.br:article/77Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:06:43Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Prevention of Oral Mucositis in Patients undergoing Chemotherapy
Prevención de la Mucositis Oral en Pacientes sometidos a la Quimioterapia
Prevenção da Mucosite Oral em Pacientes submetidos à Quimioterapia
title Prevention of Oral Mucositis in Patients undergoing Chemotherapy
spellingShingle Prevention of Oral Mucositis in Patients undergoing Chemotherapy
Valduga, Francielli
Mucosite
Prevenção & Controle
Clorexidina
Malva
Mucositis
Prevention & control
Chlorhexidine
Malva
Mucositis
Prevención & control
Clorhexidina
Malva
title_short Prevention of Oral Mucositis in Patients undergoing Chemotherapy
title_full Prevention of Oral Mucositis in Patients undergoing Chemotherapy
title_fullStr Prevention of Oral Mucositis in Patients undergoing Chemotherapy
title_full_unstemmed Prevention of Oral Mucositis in Patients undergoing Chemotherapy
title_sort Prevention of Oral Mucositis in Patients undergoing Chemotherapy
author Valduga, Francielli
author_facet Valduga, Francielli
Oltramari, Elenusa
Lemes, Letícia Tainá de Oliveira
Mattos, Carlos Eduardo de
Stefenon, Letícia
Mozzini, Carolina Barreto
author_role author
author2 Oltramari, Elenusa
Lemes, Letícia Tainá de Oliveira
Mattos, Carlos Eduardo de
Stefenon, Letícia
Mozzini, Carolina Barreto
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Valduga, Francielli
Oltramari, Elenusa
Lemes, Letícia Tainá de Oliveira
Mattos, Carlos Eduardo de
Stefenon, Letícia
Mozzini, Carolina Barreto
dc.subject.por.fl_str_mv Mucosite
Prevenção & Controle
Clorexidina
Malva
Mucositis
Prevention & control
Chlorhexidine
Malva
Mucositis
Prevención & control
Clorhexidina
Malva
topic Mucosite
Prevenção & Controle
Clorexidina
Malva
Mucositis
Prevention & control
Chlorhexidine
Malva
Mucositis
Prevención & control
Clorhexidina
Malva
description Introduction: The chemotherapy is one of the cancer possible treatments and use chemotherapeutic drugs as 5-fluorouracil (5-FU), major cause of oral mucositis. This complication is the most common cause of pain.  There is still no specific protocol for the prevention of this complication, but there are substances used empirically and palliative. Objective: Assessing the degree of mucositis during the 10 days after each chemotherapy cycle using the self-perception of each patient and the pain level reported with the use of the two substances studied: mallow tea and 0,12% chlorhexidine. Method: The selected patients were randomly randomized to perform mouthwash with 10 ml of the test substance, 3 times a day, during the infusion time of chemotherapy. In each accompanied cycle one of the studied substances were used. During the 10 days after chemotherapy, patients answered a questionnaire with closed questions about their pain and self-perception of their oral mucosa. Results: in cycles where mallow tea was used, selfperception of patients seems to be better with your oral mucositis is grade 1 and 2. However, in cycles where 0,12% chlorhexidine was used, patients experienced less pain. Conclusion: In both cycles that was used at 0.12% chlorhexidine was used as those where the mauve tea, most of the patients reported oral mucositis present. However, when used mauve tea was obtained mucositis in minor degrees. The 0.12% chlorhexidine it appeared to have less pain symptoms, although the difference was small when compared to the two substances. 
publishDate 2018
dc.date.none.fl_str_mv 2018-06-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/77
10.32635/2176-9745.RBC.2018v64n2.77
url https://rbc.inca.gov.br/index.php/revista/article/view/77
identifier_str_mv 10.32635/2176-9745.RBC.2018v64n2.77
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/77/37
https://rbc.inca.gov.br/index.php/revista/article/view/77/153
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 64 No. 2 (2018): Apr./May/June; 189-194
Revista Brasileira de Cancerologia; Vol. 64 Núm. 2 (2018): abr./mayo/jun.; 189-194
Revista Brasileira de Cancerologia; v. 64 n. 2 (2018): abr./maio/jun.; 189-194
2176-9745
10.32635/2176-9745.RBC.2018v64n2
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042242172485632